市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | BioCardia, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.3 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -3.9 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.90 |
|
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 21.66% |
| 机构持股比例 | 4.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Pingora Partners Llc | 30 Jun 2026 | 120,382 |
| Brown Advisory Inc | 30 Jun 2026 | 35,538 |
| Wealth Enhancement Advisory Services, Llc | 30 Sep 2026 | 18,500 |
该时间范围内无数据。
该时间范围内无数据。
投资组合